Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06083571 · ClinicalTrials.gov registry record · Phase 2
Intranasal Ketorolac Trial
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT06083571 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 41 participants.
The verdict
NCT06083571, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if intranasal (IN) Ketorolac in combination with oral Prochlorperazine and Diphenhydramine is non-inferior to current migraine management which involves use of intravenous (IV) Ketorolac and oral adjuncts Prochlorperazine and diphenhydramine for reducing pain intensity in children with migraine headaches. The investigators hypothesize that IN ketorolac combined with these oral adjuncts is non-inferior to IV ketorolac and oral adjuncts in reducing acute migraine headache pain by a minimum clinically significant difference within 60 minutes of administration.
Interventions
- DRUG Ketorolac
- DRUG Diphenhydramine
- DRUG Prochlorperazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06083571
The ClinicalTrials.gov registry entry for NCT06083571 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketorolac is the first listed.
NCT06083571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06083571 about?
NCT06083571 is a clinical study titled "Intranasal Ketorolac Trial". The purpose of this study is to determine if intranasal (IN) Ketorolac in combination with oral Prochlorperazine and Diphenhydramine is non-inferior to current migraine management which involves use of intravenous (IV) Ketorolac and oral adjuncts Prochlorperazine and diphenhydramine for reducing pai...
What is the current status of trial NCT06083571?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2024-01-01. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT06083571?
The interventions under investigation include: Ketorolac (DRUG), Diphenhydramine (DRUG), Prochlorperazine (DRUG).
Who is sponsoring clinical trial NCT06083571?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.